Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

The CT flare response of metastatic bone disease in prostate cancer

(2011) Christina Messiou et al.   ACTA RADIOLOGICA

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature

(2011) Christophe Le Tourneau et al.   EUROPEAN JOURNAL OF CANCER

Tumour growth rates and RECIST criteria in early drug development

(2011) Carlos Gomez-Roca et al.   EUROPEAN JOURNAL OF CANCER

Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors

(2011) Marc Buyse et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing oncologic benefit in clinical trials of immunotherapy agents

(2010) R. K. Hales et al.   ANNALS OF ONCOLOGY

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

(2008) Simon J. Crabb et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE